Bharat Biotech’s intranasal Covid vaccine to be launched on 26 January; here’s all you need to know

Bharat Biotech’s iNCOVACC intranasal Covid vaccine will be launched on January 26, PTI news agency has reported, citing the company’s president and chief executive officer, Krishna Ella.

While interacting with students at the Indian International Science Festival in Bhopal, Ella also said that a homemade vaccine for cellulitis in cattle, Lumpi-ProVacInd, could be on the market in next month.

“Our nasal drop vaccine will officially launch on January 26, on Republic Day,” said Ella while participating in the IISF’s ‘Facing new frontiers in science’ segment, which held at the Maulana Azad National Institute of Technology (MANIT), as reported by PTI.

Here’s everything you need to know about India’s first Covid vaccine:

iNCOVACC is a recombinant replication-deficient adenovirus vector vaccine with a spike protein that is stable prior to fusing. This vaccine candidate has been evaluated in phase I, II, and III clinical trials with successful results.

The vaccine was developed in collaboration with the University of Washington, St. Louis, which designed and developed the recombinant adenovirus vector construct and evaluated in preclinical studies for efficacy.

The nasal spray vaccine is stable at 2-8°C for easy storage and distribution, and is designed for efficient delivery and easy, painless administration.

This vaccine has been specially formulated to allow nasal administration via nasal drops. The nasal delivery system has been designed and developed to be cost-effective in low- and middle-income countries.

According to the company, iNCOVAC is the world’s first intranasal vaccine for covid-19 approved for a two-dose schedule and as a different booster dose.

As a needle-free vaccine, iNCOVAC will be the first such booster dose in India.

India will now have more options when it comes to the third or preventive dose.

INCOVACC’s manufacturing platform has the dual benefit of enabling faster development of variant-specific vaccines and easy intranasal delivery, enabling mass vaccination to provide protection from variants worrisome emerging

In December, Bharat Biotech announced that it will sell the nasal drop vaccine to $325 per government procurement and $800 per injection for private vaccination centers.

A report published in the journal Nature has shown that, “Intramuscular injections promote an immune response that includes T cells that destroy infected cells and B cells that produce antibodies.” ‘neutralize’ the pathogen. “

catch them all Business newsletter, Market News, Hot news Events and Latest news Update on Live Mint. Download Mint . News Application to get Daily Market Updates.

Less than


News5s: Update the world's latest breaking news online of the day, breaking news, politics, society today, international mainstream news .Updated news 24/7: Entertainment, the World everyday world. Hot news, images, video clips that are updated quickly and reliably

Related Articles

Back to top button